investor.genovis.com

Genovis Investor Relations » Investor Relations

Fem år i sammandrag. Val av styrelse / valberedning. Ändr: -0.04 (-1.44%) / Köp: 2.73 / Sälj: 2.77 / Senast: 2.73 / Högst: 2.75 / Lägst: 2.71 / Antal: 14920 / Oms.: 40656 / Valuta: SEK / 2017-01-13 16:51 (CET). GENOVIS BYTER CERTIFIED ADVISER. Genovis har tecknat licensavtal med Life Technologies Corporation. Genovis och Promega har ingått förlikning och tecknat ett globalt licensavtal. ÖKAD FÖRSÄLJNING OCH KRAFTIGT FÖRBÄTTRAT RESULTAT. HALVÅRSRAPPORT JANUARI JUNI 2016. Tel: 46 46 10 12 30.

http://investor.genovis.com/

OVERVIEW OF investor.genovis.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

18

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.GENOVIS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Sunday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.6 out of 5 with 5 reviews

5 star

0

4 star

3

3 star

2

2 star

0

1 star

0

Hey there! Start your review of investor.genovis.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

3.8 seconds

CONTACTS AT INVESTOR.GENOVIS.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

18

SSL

EXTERNAL LINKS

23

SITE IP

89.221.250.4

LOAD TIME

3.812 sec

SCORE

6.2

PAGE TITLE

Genovis Investor Relations » Investor Relations | investor.genovis.com Reviews

<META> DESCRIPTION

Fem år i sammandrag. Val av styrelse / valberedning. Ändr: -0.04 (-1.44%) / Köp: 2.73 / Sälj: 2.77 / Senast: 2.73 / Högst: 2.75 / Lägst: 2.71 / Antal: 14920 / Oms.: 40656 / Valuta: SEK / 2017-01-13 16:51 (CET). GENOVIS BYTER CERTIFIED ADVISER. Genovis har tecknat licensavtal med Life Technologies Corporation. Genovis och Promega har ingått förlikning och tecknat ett globalt licensavtal. ÖKAD FÖRSÄLJNING OCH KRAFTIGT FÖRBÄTTRAT RESULTAT. HALVÅRSRAPPORT JANUARI JUNI 2016. Tel: 46 46 10 12 30.

<META> KEYWORDS

1 bolagsöversikt

2 strategi

3 presentationer

4 bolagsstyrning

5 bolagsstämma

6 styrelse

7 verkställande ledning

8 revisorer

9 bolagsordning

10 pressmeddelande

CONTENT

Page content here

KEYWORDS ON PAGE

bolagsöversikt,strategi,presentationer,bolagsstyrning,bolagsstämma,styrelse,verkställande ledning,revisorer,bolagsordning,pressmeddelande,prenumerera,finansiella rapporter,delårsrapporter,årsredovisningar och prospekt,aktien,aktiehistorik,analytiker,nyhet

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Genovis Investor Relations » Investor Relations | investor.genovis.com Reviews

https://investor.genovis.com

Fem år i sammandrag. Val av styrelse / valberedning. Ändr: -0.04 (-1.44%) / Köp: 2.73 / Sälj: 2.77 / Senast: 2.73 / Högst: 2.75 / Lägst: 2.71 / Antal: 14920 / Oms.: 40656 / Valuta: SEK / 2017-01-13 16:51 (CET). GENOVIS BYTER CERTIFIED ADVISER. Genovis har tecknat licensavtal med Life Technologies Corporation. Genovis och Promega har ingått förlikning och tecknat ett globalt licensavtal. ÖKAD FÖRSÄLJNING OCH KRAFTIGT FÖRBÄTTRAT RESULTAT. HALVÅRSRAPPORT JANUARI JUNI 2016. Tel: 46 46 10 12 30.

INTERNAL PAGES

investor.genovis.com

1

Genovis Investor Relations » Aktieägarstruktur

http://investor.genovis.com/sv/aktien/aktieagarstruktur

Fem år i sammandrag. Val av styrelse / valberedning. FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION. Källa: Euroclear Sweden AB. Uppdaterat 2016-12-30. 1 - 5 000. 5 001 - 20 000. 20 001 - 100 000. 100 001 - 500 000. Källa: Euroclear Sweden AB. Uppdaterat 2016-12-30. Tel: 46 46 10 12 30. Fax: 46 46 12 80 20. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

2

Genovis Investor Relations » Bolagsordning

http://investor.genovis.com/sv/bolagsstyrning/bolagsordning

Fem år i sammandrag. Val av styrelse / valberedning. Val av styrelse / valberedning. Bolagsordning Genovis AB (publ) org. nr.556574-5345. Antagen vid årsstämman den 5 maj 2015. Bolagets firma är Genovis Aktiebolag (publ). Styrelsen skall ha sitt säte i Lunds kommun. Aktiekapitalet ska utgöra lägst fem miljoner tvåhundrafemtiotusen (5 250 000) kronor och högst tjugoen miljoner (21 000 000) kronor. Antalet aktier ska vara lägst tjugoen miljoner (21 000 000) och högst åttiofyra miljoner (84 000 000). För gr...

3

Genovis Investor Relations » Aktien

http://investor.genovis.com/sv/aktien

Fem år i sammandrag. Val av styrelse / valberedning. Genovis aktie handlas på Nasdaq First North Stockholm. First North är en alternativ marknadsplats som drivs av de olika börserna som ingår i Nasdaq. Aktiekapitalet uppgår till. 13 823 540,50. 55 294 162 aktier. Tel: 46 46 10 12 30. Fax: 46 46 12 80 20. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

4

Genovis Investor Relations » Bolagsstyrning

http://investor.genovis.com/sv/bolagsstyrning

Fem år i sammandrag. Val av styrelse / valberedning. Val av styrelse / valberedning. Tel: 46 46 10 12 30. Fax: 46 46 12 80 20. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

5

Genovis Investor Relations » Fem år i sammandrag

http://investor.genovis.com/sv/bolagsoversikt/fem-ar-i-sammandrag

Fem år i sammandrag. Val av styrelse / valberedning. Fem år i sammandrag. Fem år i sammandrag. Avkastning på eget kapital (%). Avkastning på totalt kapital (%). Utdelning per aktie (SEK). Tel: 46 46 10 12 30. Fax: 46 46 12 80 20. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

UPGRADE TO PREMIUM TO VIEW 13 MORE

TOTAL PAGES IN THIS WEBSITE

18

LINKS TO THIS WEBSITE

genovis.com

Genovis » SmartEnzyme Reference Tool

http://www.genovis.com/Genovis-Enzyme-Reference-Tool

FragIT & FragIT Kit. FragIT Z & FragIT Z Kit. Antibody Drug Conjugate Characterization. FabRICATOR in QC Applications. MAb Quality in Cell Culture. Mass Spectrometric Analysis of Antibodies. Mass Spectrometric Analysis of Antibodies. Production of Fab Fragments. Generation of F(ab’)2 Fragments. FabRICATOR - removes the Fc domain by specific cleavage below the hinge region and generates an intact F(ab’)2 domain. Glycation is a non-enzymatic process where reducing sugars is added to lysine side chains or o...

blog.genovis.com

Genovis » Blog » New references on IgG glycosylation, glycation and ADC characterization using IgGZERO and FabRICATOR

http://blog.genovis.com/tag/ce-ms

New references on IgG glycosylation, glycation and ADC characterization using IgGZERO and FabRICATOR. March 23, 2016 References. New references are out using Genovis enzymes to study antibody glycation, pairing of high-mannose glycans and ADC characterization using CE-MS. Generate and purify Fab fragments from human and mouse IgG using Genovis SmartEnzymes. Monitoring mAb afucosylation using GlycINATOR. EMEA & Asia. USA & Canada. Cambridge, MA 02142.

blog.genovis.com

Genovis » Blog » Genovis Launches New Enzyme Product

http://blog.genovis.com/genovis-launches-new-enzyme-product

Genovis Launches New Enzyme Product. December 3, 2015 Press Releases. Genovis is launching a further development of GingisKHAN that will be marketed under the name GingisKHAN Fab kit. The product will be presented at the conference Antibody Engineering and Therapeutics in San Diego next week. Today, about 80 percent of all antibody-based drugs are based on IgG1 molecules, human immunoglobulin of subclass 1, which is also the most common antibody in the natural composition of human antibodies.

blog.genovis.com

Genovis » Blog » New reference of FabRICATOR in antibody based PET imaging

http://blog.genovis.com/tag/application

New reference of FabRICATOR in antibody based PET imaging. February 23, 2016 References. Generate and purify Fab fragments from human and mouse IgG using Genovis SmartEnzymes. Monitoring mAb afucosylation using GlycINATOR. EMEA & Asia. USA & Canada. Cambridge, MA 02142.

blog.genovis.com

Genovis » Blog » The Genovis team has published a review on FabRICATOR (IdeS) characterization of therapeutic antibodies

http://blog.genovis.com/the-genovis-team-has-published-a-review-on-fabricator-ides-characterization-of-therapeutic-antibodies

The Genovis team has published a review on FabRICATOR (IdeS) characterization of therapeutic antibodies. May 17, 2016 References. The Genovis team has together with Alain Beck, Senior Director Antibody Physico-Chemistry at Pierre Fabre, published a review article summarizing all the current publications using FabRICATOR (IdeS) for characterization of therapeutic antibodies and related products. Drug antibody ratio on ADCs. Learn more on the FabRICATOR enzyme. Find the publication here. EMEA & Asia.

blog.genovis.com

Genovis » Blog » Genovis Launches New Enzyme Product

http://blog.genovis.com/author/genovis

Genovis Launches New Enzyme Product. December 3, 2015 Press Releases. Genovis is launching a further development of GingisKHAN that will be marketed under the name GingisKHAN Fab kit. The product will be presented at the conference Antibody Engineering and Therapeutics in San Diego next week. Genovis AB (publ) to Publish Q3 2015 Report Ahead of Schedule. October 23, 2015 Press Releases. The Board of Directors of Genovis AB (publ) has decided to publish Q3 2015 report ahead of schedule. EMEA & Asia.

blog.genovis.com

Genovis » Blog » New reference of FabRICATOR in antibody based PET imaging

http://blog.genovis.com/new-reference-of-fabricator-in-antibody-based-pet-imaging

New reference of FabRICATOR in antibody based PET imaging. February 23, 2016 References. In PET imaging applications a short half life of the antibody is desirable, as this decreases the background signal. The fusion protein demonstrated reduced half-life of about 2h, retained antigen binding capacities and successfully detected levels of amyloid beta in the brains of two different mouse models of Alzheimers. Find the full report on the link below:. Monitoring mAb afucosylation using GlycINATOR.

blog.genovis.com

Genovis » Blog » Generate and purify Fab fragments from human and mouse IgG using Genovis SmartEnzymes

http://blog.genovis.com/category/references

Articles in the Category References. Generate and purify Fab fragments from human and mouse IgG using Genovis SmartEnzymes. March 1, 2017 Products. Antibodies are important tools in several scientific research areas, and sometimes it is necessary to cleave antibodies to generate antigen binding (Fab) fragments. The Fab fragments can be used within e.g. imaging, removal of effector functions, infection biology, binding studies, and mass spectrometry. In a recently published book (. Sjögren, J. et al&#...

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL LINKS TO THIS WEBSITE

23

OTHER SITES

investor.generalcable.com

General Cable - Investor Relations - Investor Information

Also, please be aware that reports and information relating to Investor Relations may contain forward-looking statements. We call your attention to our Safe Harbor caution for forward-looking statements that you will find at the end of every press release and in our annual report on Form 10K on file with the SEC. The Safe Harbor caution identifies factors and risks that may cause our actual results to differ materially from the content of our forward-looking statements.

investor.generalmoly.com

General Moly : Investor Relations : Corporate Overview

Transfer Agents and Services. Quarterly Reports and Webcasts. General Moly at Jefferies 2015 Industrials Conference. 160;at 10:40 am ET. General Moly at Jefferies 2015 Industrials Conference. Wednesday, August 12, 2015 . 10:40 am ET . Click here for webcast. Â Click here to add this event to your calendar. Most Recent Corporate Presentation. Annual Meeting of Stockholders Presentation. General Moly to Attend the Jefferies Industrials Conference. General Moly Announces Second Quarter 2015 Results.

investor.generex.com

Generex Biotechnology Corporation - Investor Home

Large Molecule Drugs Challenge. Jun 24, 2015. Generex Announces Capital Investment. May 26, 2015. Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist™ Buccal Delivery Technology for Leuprolide. May 14, 2015. Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment. Raquo; Investor Home. For more information please contact:. 44 West Lancaster Avenue. Ardmore, PA 19003. Eckert Seamans Cherin and Mellott, LLC. Philadelphia, PA 19102.

investor.genomichealth.com

Investors | Genomic Health, Inc.

United States - English. United States - English. United Kingdom - English. Genomic Health is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Company Timeline and Milestones. Genomic Health and Oncotype IQ - Delivering Precision Medicine. Watch how Genomic Health continues to transform cancer care around the world. World Class Commercial Channel. Watch CEO Kim Po...

investor.genoptix.com

Genoptix Medical Laboratory - Company Information

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix’s highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering...

investor.genovis.com

Genovis Investor Relations » Investor Relations

Fem år i sammandrag. Val av styrelse / valberedning. Ändr: -0.04 (-1.44%) / Köp: 2.73 / Sälj: 2.77 / Senast: 2.73 / Högst: 2.75 / Lägst: 2.71 / Antal: 14920 / Oms.: 40656 / Valuta: SEK / 2017-01-13 16:51 (CET). GENOVIS BYTER CERTIFIED ADVISER. Genovis har tecknat licensavtal med Life Technologies Corporation. Genovis och Promega har ingått förlikning och tecknat ett globalt licensavtal. ÖKAD FÖRSÄLJNING OCH KRAFTIGT FÖRBÄTTRAT RESULTAT. HALVÅRSRAPPORT JANUARI JUNI 2016. Tel: 46 46 10 12 30.

investor.genworth.com

Genworth Financial - Investors

Stock Quote and Chart. Stock Purchase / Dividend Reinvestment. Dividends and Stock Splits. Code of Business Conduct and Ethics. Political Contributions and Expenditures. 2017 Annual Meeting Of Stockholders Results. 2017 Special Meeting Of Stockholders Results. Welcome to Genworth Investor Relations. Genworth remains committed to helping families become more financially secure, self-reliant and prepared for the future. Genworth 4Q17 Earning Summary Presentation (Feb 7). View all press releases.

investor.genworth.com.au

Genworth - Investor Centre

About Genworth and LMI. What is Lenders Mortgage Insurance? How can Lenders Mortgage Insurance benefit me? Lenders Mortgage Insurance FAQs. Lenders Mortgage Insurance endorsements. Partnership and Distribution team. Genworth in the community. Investor and international news. MFAA National Convention 2015. Share price and tools. Share price and graph. Online tools, forms and reports. LMI Proposal and Variation Requests. Homeowner Assistance Program (HOAP). Policy and process information. How to sell LMI.

investor.genworthmicanada.ca

Genworth MI Canada - Home

Feb 7, 2018 10:30 AM ET. Q4 REPORT NOW AVAILABLE. December 6, 2017. Annual General Meeting of Shareholders. June 8, 2017 10:00am ET. Education and Financial Literacy. Community and Civic Responsibility. Compensation and Nominating Committee. Risk, Capital and Investment Committee. PANEL 1: Driving Core Growth. PANEL 2: Proactively Mitigating Risk. PANEL 3: Sustaining Profitability. March 5, 2018 -. National Meaning of Home youth writing contest raises $170,000 for Habitat for Humanity. February 6, 2018 -.

investor.ggp.com

GGP Investor Center

Kiosks, Carts and Specialty Leasing. GGP in the Community. Properties keyboard arrow right. Leasing keyboard arrow right. Kiosks, Carts and Specialty Leasing. Advertising keyboard arrow right. Investors keyboard arrow right. About GGP keyboard arrow right. GGP in the Community. GGP’s mission is to own and operate best-in-class retail properties that provide an outstanding environment and experience for our communities, retailers, employees, consumers and shareholders. View our latest Investor Presentation.

investor.gidynamics.com

GIDynamics, Inc. - Investors

Skip to main content. GI Dynamics, Inc. Company Overview. GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically-delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. Enter the code shown above. Email Alert Sign Up Confirmation. Boston, MA 02210.